Youngwill Technology Secures Tens of Millions in Series A Funding to Advance Dermatology-focused Digital Therapeutics and Care Pathway Management

VCBeat has learned that Hangzhou Yongliu Technology Co., Ltd. (“Yongliu Tech”), a medical technology and professional service platform company specializing in dermatology disease course management and digital therapeutics, announced today the completion of its RMB tens-of-millions Series A financing round. The round was solely led by HongShan, with participation from Hangzhou Wanlun Shangde, while MARATHON VENTURE PARTNERS, the investor from the angel round, continued to increase its investment. Yongliu Tech stated, “The proceeds from this financing round will continue to be allocated to the development of its doctor-patient service platform, the construction of its professional service system, team expansion, and market development.”

Disease course management and digital therapeutics are among the most prominent focal points in the current digital healthcare industry. As an emerging field, digital therapeutics is defined by the industry as the provision of evidence-based therapeutic interventions to patients via software programs, aimed at preventing, managing, or treating diseases. Digital therapeutic products can be used either independently or in conjunction with medications, medical devices, or other therapies. These products integrate evidence-based clinical guidelines for specific diseases, cutting-edge digital technologies, and the latest advancements in data security, and are subject to review and approval by government regulatory authorities in accordance with relevant policies.

With the rapid development of innovative technologies and models, 2020 marked the inaugural year for the development of disease journey management and digital therapeutics in China’s specialized healthcare sector, ushering in a new era of industrial growth. Amidst this trend, emerging enterprises rooted in specific disease areas, equipped with professional service management capabilities and digital application expertise, will have the opportunity to contribute more significantly to the innovative development of China’s healthcare industry.

As a practitioner of this innovative development model, Yongliu Technology focuses on the field of dermatological diseases. Guided by scientific diagnostic and therapeutic pathways, and aiming to create personalized, full-course treatment plans for patients, it collaborates with medical experts, physicians, and partners across various sectors to build and develop an industry-leading disease management system for dermatology and high-value digital therapeutics products. This empowers more physicians, benefits more patients, and fosters multi-party win-win development.

Yongliu Technology is a platform-based enterprise dedicated to providing personalized disease course management solutions for patient populations in specific disease areas through advanced digital technology applications and comprehensive professional services in vertical disease fields, while offering doctors one-stop services for clinical practice, teaching, and scientific research.

As “entrepreneurs behind entrepreneurs,” HongShan China Fund focuses on investment opportunities in three sectors: TMT, healthcare, and consumer goods/services. With over a decade of in-depth research and systematic investment deployment, HongShan China has invested in nearly 180 outstanding companies in the healthcare sector. Its investment portfolio spans multiple subsectors, including innovative drugs, medical devices, healthcare services, precision medicine, and digital health.

MARATHON VENTURE PARTNERS is an early-stage venture capital fund focused on the digital health and medical technology sector. To date, MARATHON has invested in over 40 companies that are leveraging digital technologies to drive structural change in access, efficiency, and payment within China’s healthcare industry.

As a core component of the Wanlun Innovation Fund, Wanlun Shangde is committed to providing one-stop capital support and services to high-quality life science enterprises in China, building a collaborative ecosystem for the biomedical and broader life health industry clusters, and facilitating the high-quality development of its partner companies.